Dr. Thomas Cannell, President & CEO of Sesen Bio, & Dr. Michael Jewett, FRCSC, FACS, to Participate in Canaccord Genuity “H...
April 08 2021 - 8:55AM
Business Wire
Sesen Bio (Nasdaq: SESN), a late-stage clinical company
developing targeted fusion protein therapeutics for the treatment
of patients with cancer, today announced it will be featured as a
presenting company at the Canaccord Genuity “Horizons in Oncology”
virtual conference on April 15, 2021. Sesen Bio will be represented
by Dr. Thomas Cannell, President and CEO of Sesen Bio, who will
provide a regulatory and commercial readiness update, and by Dr.
Michael Jewett, FRCSC, FACS, a member of Sesen Bio’s CEO Medical
advisory board, who will provide clinical insights on the Company’s
lead product candidate, Vicineum™, for the treatment of
BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
Michael A. S. Jewett, MD, FRCSC, FACS is a renowned Oncologist
who is internationally recognized for his life-saving innovations
in surgical oncology, his advocacy of patient-centered clinical
care, and his contributions to research in the field of bladder
cancer. Dr. Jewett is currently a professor in the Departments of
Surgical Oncology and Surgery (Urology) at the Princess Margaret
Cancer Centre, University Health Network and the University of
Toronto. A graduate of Queen’s University, Faculty of Medicine,
Kingston, Ontario, Canada, where BCG for bladder cancer was first
prescribed, Dr. Jewett completed his Urology training at the
University of Toronto, Canada and Memorial Sloane-Kettering Cancer
Center in New York. Dr. Jewett has played a prominent role in
national and international consensus statements, including as a
committee chair for the International Consultation on Bladder
Tumors in 2004 Consensus. He has appeared before the FDA as an
expert including the presentation that led to the historic approval
of BCG for NMIBC. Dr. Jewett has published more than 400
peer-reviewed papers, mostly in Uro-oncology and in technology
assessment and medical informatics. Dr Jewett was a member of the
inaugural Medical Advisory Board of the Bladder Cancer Advocacy
Network (BCAN). He is an Honorary Member of the American Urological
Association (AUA) and the European Association of Urology (EAU) and
has been a visiting professor in more than 40 institutions and
associations. In December 2020, Dr. Jewett was appointed to the
Order of Canada based on his achievements listed above, among
others. Dr. Jewett is a paid consultant to Sesen Bio and served as
a clinical investigator for the Phase 1 and Phase 2 clinical trials
of Vicineum for NMIBC.
Event: Canaccord Genuity “Horizons in Oncology” Virtual
Conference Date: April 15, 2021 Time: 9:00 – 10:00 AM
ET To participate in the event please contact your Canaccord
Genuity representative.
About Vicineum™
Vicineum, a locally administered fusion protein, is Sesen Bio’s
lead product candidate being developed for the treatment of
BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
Vicineum is comprised of a recombinant fusion protein that targets
epithelial cell adhesion molecule (EpCAM) antigens on the surface
of tumor cells to deliver a potent protein payload, Pseudomonas
Exotoxin A. Vicineum is constructed with a stable, genetically
engineered peptide tether to ensure the payload remains attached
until it is internalized by the cancer cell, which is believed to
decrease the risk of toxicity to healthy tissues, thereby improving
its safety. In prior clinical trials conducted by Sesen Bio, EpCAM
has been shown to be overexpressed in NMIBC cells with minimal to
no EpCAM expression observed on normal bladder cells. Sesen Bio is
currently in the follow-up stage of a Phase 3 registration trial in
the US for the treatment of BCG-unresponsive NMIBC. In February
2021, the FDA accepted for filing the Company’s BLA for Vicineum
for the treatment of BCG-unresponsive NMIBC and granted the
application Priority Review with a PDUFA date of August 18, 2021.
Additionally, Sesen Bio believes that cancer cell-killing
properties of Vicineum promote an anti-tumor immune response that
may potentially combine well with immuno-oncology drugs, such as
checkpoint inhibitors. For this reason, the activity of Vicineum in
BCG-unresponsive NMIBC is also being explored at the US National
Cancer Institute in combination with AstraZeneca’s immune
checkpoint inhibitor durvalumab.
About Sesen Bio
Sesen Bio, Inc. is a late-stage clinical company advancing
targeted fusion protein therapeutics for the treatment of patients
with cancer. The Company’s lead program, Vicineum™, also known as
VB4-845, is currently in the follow-up stage of a Phase 3
registration trial for the treatment of BCG-unresponsive non-muscle
invasive bladder cancer (NMIBC). In February 2021, the FDA accepted
for filing the Company’s BLA for Vicineum for the treatment of
BCG-unresponsive NMIBC and granted the application Priority Review
with a PDUFA date of August 18, 2021. Sesen Bio retains worldwide
rights to Vicineum with the exception of Greater China and the
Middle East and North Africa (MENA), for which the Company has
partnered with Qilu Pharmaceutical and Hikma Pharmaceuticals,
respectively, for commercialization. Vicineum is a locally
administered targeted fusion protein composed of an anti-EpCAM
antibody fragment tethered to a truncated form of Pseudomonas
Exotoxin A for the treatment of BCG-unresponsive NMIBC. For more
information, please visit the company’s website at
www.sesenbio.com.
COVID-19 Pandemic Potential Impact
Sesen Bio continues to monitor the rapidly evolving environment
regarding the potential impact of the COVID-19 pandemic on our
Company. The Company has not yet experienced any disruptions to our
operations as a result of COVID-19, however, we are not able to
quantify or predict with certainty the overall scope of potential
impacts to our business, including, but not limited to, our ability
to raise capital and, if approved, commercialize Vicineum. Sesen
Bio remains committed to the health and safety of patients,
caregivers and employees.
Cautionary Note on Forward-Looking Statements
Any statements in this press release about future expectations,
plans and prospects for the Company, the Company’s strategy, future
operations, and other statements containing the words “anticipate,”
“believe,” “estimate,” “expect,” “intend,” “may,” “plan,”
“predict,” “project,” “target,” “potential,” “will,” “would,”
“could,” “should,” “continue,” and similar expressions, constitute
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, including: the timing for
the FDA’s decision on the Company’s BLA for Vicineum for the
treatment of BCG unresponsive NMIBC based on the FDA granting the
BLA Priority Review and the PDUFA date of August 18, 2021, the
impact of COVID-19 on the Company, including its ability to raise
capital, and, if approved, its ability to commercialize Vicineum
for the treatment of BCG unresponsive NMIBC, and other factors
discussed in the “Risk Factors” section of the Company’s Annual
Report on Form 10-K, filed with the Securities and Exchange
Commission. In addition, the forward-looking statements included in
this press release represent the Company’s views as of the date
hereof. The Company anticipates that subsequent events and
developments will cause the Company’s views to change. However,
while the Company may elect to update these forward-looking
statements at some point in the future, the Company specifically
disclaims any obligation to do so. These forward-looking statements
should not be relied upon as representing the Company’s views as of
any date subsequent to the date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210408005534/en/
Erin Clark, Vice President, Corporate Strategy & Investor
Relations ir@sesenbio.com
Sesen Bio (NASDAQ:SESN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sesen Bio (NASDAQ:SESN)
Historical Stock Chart
From Apr 2023 to Apr 2024